GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EOM Pharmaceutical Holdings Inc (OTCPK:IMUC) » Definitions » Tangible Book per Share

EOM Pharmaceutical Holdings (EOM Pharmaceutical Holdings) Tangible Book per Share : $0.82 (As of Jun. 2018)


View and export this data going back to 2006. Start your Free Trial

What is EOM Pharmaceutical Holdings Tangible Book per Share?

Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. EOM Pharmaceutical Holdings's tangible book value per share for the quarter that ended in Jun. 2018 was $0.82.

Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


EOM Pharmaceutical Holdings Tangible Book per Share Historical Data

The historical data trend for EOM Pharmaceutical Holdings's Tangible Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EOM Pharmaceutical Holdings Tangible Book per Share Chart

EOM Pharmaceutical Holdings Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Tangible Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 184.03 146.48 96.20 17.80 1.11

EOM Pharmaceutical Holdings Quarterly Data
Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18
Tangible Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.27 -0.22 1.11 0.88 0.82

Competitive Comparison of EOM Pharmaceutical Holdings's Tangible Book per Share

For the Biotechnology subindustry, EOM Pharmaceutical Holdings's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EOM Pharmaceutical Holdings's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EOM Pharmaceutical Holdings's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where EOM Pharmaceutical Holdings's Price-to-Tangible-Book falls into.



EOM Pharmaceutical Holdings Tangible Book per Share Calculation

EOM Pharmaceutical Holdings's Tangible Book Value Per Share for the fiscal year that ended in Dec. 2017 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(4.648-0-0)/4.19132
=1.11

EOM Pharmaceutical Holdings's Tangible Book Value Per Share for the quarter that ended in Jun. 2018 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(3.427-0-0)/4.19132
=0.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


EOM Pharmaceutical Holdings  (OTCPK:IMUC) Tangible Book per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


EOM Pharmaceutical Holdings Tangible Book per Share Related Terms

Thank you for viewing the detailed overview of EOM Pharmaceutical Holdings's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


EOM Pharmaceutical Holdings (EOM Pharmaceutical Holdings) Business Description

Traded in Other Exchanges
N/A
Address
136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645
EOM Pharmaceutical Holdings Inc is focused on developing novel immunomodulatory and retinal disease drug agents to address a range of inflammatory, viral, retinal, and other diseases. Its product candidate includes dual-acting broad-spectrum immunomodulator EOM613, which has the potential to treat cancer cachexia and rheumatoid arthritis, and its advanced formulation of EOM147 is being studied to treat serious retinal diseases without the need for intraocular injection.
Executives
Andrew Gengos director 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Gary Titus director, officer: Chairman and Secretary SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Mark A Schlossberg director C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Rahul Singhvi director 246 HOLLY DRIVE, CHALFONT PA 18914
Helen Susan Kim director 3832 BAY CENTER PLACE, HAYWARD CA 94545
Richard Chin director C/O OXIGENE, INC., 230 THIRD AVENUE, WALTHAM MA 02451
Richard Cowell director 7840 VIRGINIA OAK DRIVE, GAINSVILLE VA 20155
James G. Bender officer: VP, Product Development & Mfg. 112 WEST 34TH STREET, 17TH FLOOR, NEW YORK NY 10120
Manish Singh director, officer: President & CEO 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Jacqueline Brandwynne director 649 STONE CANYON ROAD, LOS ANGELES CA 90077